Best Practices to Incorporate Diversity and Inclusion in MedTech
Watch this on-demand webinar by Alira Health in partnership with MassMEDIC to get an insight into the topic of diversity and inclusion as it applies across the product lifecycle, identify structural and operational barriers to improved representation, and highlight how technology and decentralized approaches to clinical trials and patient engagement can bridge the gap.
The FDA’s recent release of “Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials: Guidance for Industry” reflects the increasing importance of implementing a patient-centric approach throughout the product lifecycle. To address the diversity of the US population, sponsors quickly find themselves in a complex ecosystem of patient characteristics that include social determinants of health, mistrust in the medical community and research process, unequal access to care, under-represented and under-diagnosed minority populations, co-morbidity, and more.
Nada HanafiSVP Regulatory Strategy, Veranex & Co-Founder and Board Director, MedTech Color
Kathleen TroegerSenior Director, Real-World Evidence, Medical Device and Diagnostics, Aetion
Jaime WheelerSr. VP Global Clinical Affairs, Edwards Lifesciences
Neely WilliamsCommunity Partner Consultant at NIH, PCORI & PCORnet
Renee WillmonSenior Director Evidence & Outcomes, Alira Health
More Clinical Diversity Resources
Diversity in Clinical Trials: A Blog Series
To gain the latest insights on the impact, challenges, and strategies, we are pleased to bring you a new series on “Diversity in Clinical Trials” with Jennifer Lannon, Director of Partnerships and Business Development, Patient Advocacy at Alira Health.